From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
Transition | Baseline | Range | Reference |
---|---|---|---|
Chronic Hepatitis C | Â | Â | Â |
 to Compensated Cirrhosis | 7.30 % | 1.0 %-23.2 % | |
Compensated Cirrhosis | Â | Â | Â |
 to Decompensated Cirrhosis | 3.90 % | 2.0 %-8.3 % | |
 to HCC | 3.70 % | 1.0 %-4.4 % | |
Decompensated Cirrhosis | Â | Â | Â |
 to HCC | 3.70 % | 1.0 %-4.4 % | |
 to Liver Transplant | 3 % | 1.0 %-6.2 % | |
 to Liver-induced Death | 12.90 % | 6.5 %-19.3 % | |
HCC | Â | Â | Â |
 to Liver Transplant | 3 % | 1.0-6.2 % | |
 to Liver-induced Death | 42.70 % | 33 %-86 % | |
Liver Transplant | Â | Â | Â |
 to Liver-induced Death, first year | 13.70 % | 6 %-42 % | |
 to Liver-induced Death, successive year | 5.20 % | 2.4 %-11 % |